Aeolus Files International Patent Application for New Patent on AEOL 10150

MISSION VIEJO, CA--(Marketwired - December 03, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)

• Filing covers synthesis, formulation and pharmaceutical composition
• Could significantly increase term of patent protection for AEOL 10150

Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has filed an international patent application under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO) thereby preserving the right to seek patent protection in all PCT contracting countries for new patents covering new inventions resulting from research and development on its lead compound, AEOL 10150. Patents resulting from this application, if granted, would cover novel synthesis routes, crystal forms and pharmaceutical compositions of AEOL-10150 and related porphyrin compounds. The intellectual property underlying this new patent filing is a direct result of work performed under Aeolus' contract with the Biomedical Advanced Research and Development Authority ("BARDA"). The five year, $118 million, cost-plus contract, awarded in February 2011, includes funding for the development of large-scale, Good Manufacturing Practice production capacity for AEOL 10150. 

"These new patents, if granted, would substantially increase the life of the patent protection surrounding AEOL 10150 throughout the world," stated John McManus, Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "Extended patent life would open up new potential strategic options for our AEOL 10150 radiation therapy and lung fibrosis development programs. The work that led to this filing is an excellent example of the value that BARDA brings as a partner in advanced drug development."

About AEOL 10150

AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation and subsequent tissue damage resulting from radiation exposure. The Company believes that AEOL 10150 could have a profound beneficial impact on people who are exposed to high doses of radiation.

AEOL 10150 has already performed well in animal safety studies, was well tolerated in two human clinical trials and has demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Aeolus has received "Orphan Drug" designation for the use of AEOL 10150 in treating lung ARS, and will file an IND to allow for human safety testing in patients receiving radiation and chemotherapy for cancer within the next several months.